Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials by Scheres, L.J.J. et al.
Res Pract Thromb Haemost. 2018;2:689–695.	 	 	 | 	689wileyonlinelibrary.com/journal/rth2
 
Received:	16	May	2018  |  Accepted:	29	June	2018
DOI: 10.1002/rth2.12142
B R I E F  R E P O R T
Measurement of coagulation factors during rivaroxaban and 
apixaban treatment: Results from two crossover trials
Luuk J. J. Scheres MD1,2  | Willem M. Lijfering MD, PhD2,3 | Saskia Middeldorp MD, PhD1  |  
Yuk W. Cheung MD, PhD1 | Stefano Barco MD, PhD1,4  | Suzanne C. Cannegieter MD, 
PhD2,3  | Michiel Coppens MD, PhD1
This	is	an	open	access	article	under	the	terms	of	the	Creative	Commons	Attribution-NonCommercial-NoDerivs	License,	which	permits	use	and	distribution	in	
any	medium,	provided	the	original	work	is	properly	cited,	the	use	is	non-	commercial	and	no	modifications	or	adaptations	are	made.
©	2018	The	Authors.	Research and Practice in Thrombosis and Haemostasis	published	by	Wiley	Periodicals,	Inc	on	behalf	of	International	Society	on	Thrombosis	
and Haemostasis.
1Department	of	Vascular	
Medicine,	Academic	Medical	Center,	
Amsterdam,	the	Netherlands
2Department	of	Clinical	
Epidemiology,	Leiden	University	Medical	
Center,	Leiden,	the	Netherlands
3Department	of	Internal	Medicine,	Section	
Thrombosis	and	Hemostasis,	Leiden	
University	Medical	Center,	Leiden,	the	
Netherlands
4Center	for	Thrombosis	and	
Hemostasis,	University	Medical	Center	of	
the	Johannes	Gutenberg	University,	Mainz,	
Germany
Correspondence
Luuk	J.	J.	Scheres,	Department	of	Clinical	
Epidemiology,	Leiden	University	Medical	
Center,	Leiden,	the	Netherlands.
Email: l.j.j.scheres@lumc.nl
Funding Information 
The	original	rivaroxaban	study	by	Barco	et	al	
was	funded	the	Netherlands	Organisation	
for	Health	Research	and	Development	
(project	number	836021017)	and	Sanquin	
Blood	Supply.	The	original	apixaban	study	by	
Cheung	et	al	was	funded	by	the	Netherlands	
Organisation	for	Health	Research	and	
Development	(project	number	836021017),	
Sanquin	Blood	Supply,	and	the	Bristol-	Myers	
Squibb	Pfizer	alliance.	L.J.J.	Scheres	is	a	PhD	
candidate	supported	by	the	Netherlands	
Heart	Foundation,	CREW	project	
(2013T083).	S.	Barco	is	supported	by	the	
German	Federal	Ministry	of	Education	and	
Research	(BMBF	01EO1003	and	01EO1503).
Abstract
Background:	Prediction	models	for	venous	thromboembolism	recurrence	will	likely	
be	improved	by	adding	levels	of	coagulation	factors.	Risk	assessment	is	ideally	per-
formed	during	anticoagulant	treatment,	however,	the	influence	of	direct	oral	antico-
agulants	on	coagulation	factors	is	uncertain.
Objective:	To	assess	the	influence	of	rivaroxaban	and	apixaban	on	several	coagula-
tion	factor	levels.
Methods:	In	two	crossover	trials	we	assessed	the	influence	of	rivaroxaban	and	apixa-
ban	intake	on	factor	(F)VIII,	FXI	and	FXII-	activity	and	fibrinogen,	von	Willebrand	fac-
tor	(VWF:Ag),	and	d-	dimer	levels.	At	three	sessions	with	a	washout	period	in	between,	
blood	was	taken	from	12	healthy	male	individuals	immediately	before	intake	of	rivar-
oxaban	15	mg	twice	daily	(n	=	6)	or	apixaban	10	mg	twice	daily	(n	=	6)	and	three	hours	
after	the	last	intake.
Results:	Overall,	measured	levels	were	lower	after	rivaroxaban/apixaban	intake.	The	
paired	mean	difference	after	rivaroxaban	intake	was	−38	IU/dL	(95%	CI	−43;	−33)	for	
FVIII:C,	−29	U/dL	(95%	CI	−45;	−12)	for	FXI:C,	−22	IU/dL	(95%	CI	−43;	−1)	for	FXII:C,	
−0.11	g/L	(95%	CI	−0.25;	0.03)	for	fibrinogen,	−7	IU/dL	(95%	CI	−18;	3)	for	VWF:Ag,	
−27	ng/mL	(95%	CI	−50;	−4)	for	d-	dimer	and	−0.36	(95%	CI	−0.57;	−0.15)	for	Ln	d-	
dimer.	After	apixaban	intake	this	was	−29	IU/dL	(95%	CI	−38;	−21)	for	FVIII:C,	−29	IU/
dL	(95%	CI	−36;	−22)	for	FXI:C,	−19	IU/dL	(95%	CI	−24;	−15)	for	FXII:C,	−0.18	g/L	(95%	
CI	−0.33;	0.03)	for	fibrinogen,	−52	ng/mL	(95%	CI	−100;	−4)	for	d-	dimer,	0.25	(−0.60;	
0.09)	for	Ln	d-	dimer	and	1	IU/dL	(95%	CI	−7;	9)	for	VWF:Ag.
Conclusion:	FVIII:C,	FXI:C,	FXII:C,	and	d-	dimer	measurements	were	 influenced	by	
rivaroxaban/apixaban	intake,	while	fibrinogen	and	VWF:Ag	were	not.
K E Y W O R D S
apixaban,	blood	coagulation	tests,	coagulants,	factor	Xa	inhibitors,	risk	assessment,	
rivaroxaban
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1  | BACKGROUND
Venous	thromboembolism,	the	composite	of	deep	vein	thrombosis	
and	pulmonary	embolism,	can	be	prevented	and	treated	effectively	
with	anticoagulation	therapy.	Unfortunately,	all	currently	available	
anticoagulant	therapies	carry	the	burden	of	increased	bleeding	risk.	
After	 initial	 treatment	of	an	episode	of	venous	thromboembolism	
(typically	3-	6	months),	the	decision	to	prolong	anticoagulant	treat-
ment	must	be	weighed	against	the	bleeding	risk.1	 Ideally,	persons	
with	a	high	recurrence	risk	are	 identified	and	anticoagulant	 treat-
ment	 prolonged,	 whereas	 in	 patients	 with	 a	 low	 recurrence	 risk,	
treatment	can	be	stopped	safely.	Several	prediction	models	that	es-
timate	the	risk	of	venous	thromboembolism	recurrence	have	been	
developed,	most	of	which	perform	moderately.2 The accuracy and 
discriminative	performance	of	these	models	can	potentially	be	im-
proved	by	adding	coagulation	factors	as	predictors.	By	preference	
such	a	predictor	is	not	influenced	by	use	or	type	of	anticoagulants,	
optimizing	the	applicability	of	the	assessment	model.	Candidate	co-
agulation	 factors	 are	 factor	 (F)VIII,	 von	Willebrand	 factor	 (VWF),	
and d-	dimer	for	which	higher	 levels	are	associated	with	 increased	
recurrence	 risk.3-7	 Preferably,	 risk	 assessment	 and	 herewith	 the	
measurement	of	these	coagulation	factors	 is	performed	while	the	
patient	is	still	on	anticoagulant	treatment.	By	doing	so,	persons	at	
high	recurrence	risk	are	not	exposed	to	an	anticoagulation-	free	in-
terval	and	remain	protected	during	risk	assessment.	This	approach	
also	 seems	more	patient-	friendly	as	only	one	 (outpatient)	 contact	
moment,	 which	 can	 be	 combined	 with	 blood	 draw,	 is	 necessary.	
This	was	for	example	done	in	the	derivation	and	in	the	majority	of	
patients	in	the	validation	study	of	the	HERDOO2	model,	 in	which	
d-	dimer	levels	were	measured	on	vitamin	K	antagonist	(VKA)	treat-
ment.8,9	 Treatment	with	 VKA	 influences	 d-	dimer	 levels,	 probably	
due	 to	 its	anticoagulant	effect.10	Whether	d-	dimer	 test	 levels	are	
affected	by	direct	oral	anticoagulants	(DOACs)	is	not	well	known.	In	
contrast,	FVIII	 levels	are	non-	vitamin	K	dependent	and	seem	only	
marginally	influenced	by	VKAs,	but	may	be	affected	by	DOACs11-13 
which	are	now	suggested	as	 first	 treatment	of	 choice	 for	 venous	
thromboembolism.14	Several	previous	studies	that	investigated	the	
effect	of	DOACs	on	the	measurement	of	coagulation	factors	inves-
tigated	spiked	ex	vivo	samples	and	found	varying	results	according	
to	the	combinations	of	reagents	and	drugs.15-19	For	instance,	FVIII:C	
levels	seem	to	be	effected	by	concurrent	DOAC	use,	while	d-	dimer,	
fibrinogen,	 and	VWF:Ag	may	 not.18,19	As	DOACs	 have	 been	 rap-
idly	 implemented	 in	 clinical	 practice,	 it	 is	 of	 importance	 to	 study	
whether	 commonly	 used	measurements	 of	 coagulation	 are	 influ-
enced	by	DOAC	intake.
In	two	crossover	trials,	we	determined	whether	levels	of	FVIII:C,	
FXI:C,	FXII:C,	VWF,	 fibrinogen,	and	d-	dimer	are	 influenced	by	 the	
direct	FXa	inhibitors	rivaroxaban	and	apixaban.
2  | METHODS
2.1 | Study design
We	performed	a	post	hoc	analysis	in	two	crossover	trials	of	which	the	
main	results	were	published	previously	by	Barco	et	al20	and	Cheung	
et al21;	both	studies	are	registered	in	the	Dutch	Trial	Registry	(www.
trialregister.nl;	 NTR3559).	 In	 the	 study	 by	 Barco	 et	al,	 six	 healthy	
male	 volunteers	 received	 a	 twice	 daily	 rivaroxaban	 15	mg	 bid	 for	
2.5	days	at	three	different	sessions.	The	main	aim	of	that	study	was	
to	assess	reversal	of	treatment	with	prothrombin	complex	concen-
trate	in	two	different	dosages	compared	with	placebo.	Hence,	vol-
unteers	repeated	the	study	two	times	with	a	washout	period	of	at	
least	15	days.	The	design	 from	 the	Cheung	et	al	 study	was	 similar	
to	the	Barco	et	al	study.	Here,	six	healthy	male	volunteers	received	
twice-	daily	apixaban	10	mg	for	3.5	days	followed	by	a	single	bolus	
of	 prothrombin	 complex	 concentrate	 in	 two	 different	 dosages	 at	
three	 (one	 with	 placebo)	 different	 sessions.	 All	 participants	 pro-
vided	written	informed	consent	and	both	studies	were	approved	by	
the	Medical	Ethical	Committee	of	the	Academic	Medical	Center	in	
Amsterdam,	the	Netherlands.	For	the	current	study,	only	the	blood	
samples	drawn	just	before	DOAC	intake	and	three	hours	after	the	
last	intake	were	used	(eg,	before	the	administration	of	prothrombin	
complex	 concentrate),	 in	 total	 there	were	 two	 studies,	 six	 partici-
pants,	three	sessions,	for	a	total	of	36	blood	samples.
2.2 | Blood samples
For	 each	of	 the	 three	 sessions,	 blood	 samples	were	drawn	 imme-
diately	 before	 the	 first	 intake	 of	 rivaroxaban/apixaban	 (T	=	0,	 0′	
and	0′′)	 and	 three	hours	 after	 the	 last	 dose	of	 rivaroxaban/apixa-
ban	(T	=	1,	1′	and	1′′),	 in	vacuum	tubes	containing	0.105	mol/L	so-
dium	citrate	and	centrifuged	twice	at	2500	g	for	10	minutes	at	18°C	
within	two	hours	after	venipuncture.	After	aliquoting,	the	samples	
were	stored	at	−80°C.
2.3 | Laboratory measurements
Activity	 (:C)	of	FVIII,	FXI,	FXII	 (one	stage-	clotting),	and	VWF	anti-
gen	 (VWF:Ag)	 (imunoturbimetric),	 fibrinogen	 (Clauss	method)	 and	
Essentials
•	 It	is	uncertain	whether	direct	factor	Xa	inhibitors	influence	levels	of	coagulation	factors.
•	 In	two	trials	we	assessed	the	influence	of	rivaroxaban	and	apixaban	on	coagulation	factor	levels.
•	 Factors	VIII,	XI,	XII,	and	d-dimer	measurements	were	influenced	by	rivaroxaban/apixaban	intake.
•	 Fibrinogen	and	von	Willebrand	factor	measurements	were	not	affected	by	rivaroxaban/apixaban	use.
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d-	dimer	(imunoturbimetric)	levels	were	measured	using	the	ACL	TOP	
700	analyzer	(Werfen	Instrumentation	Laboratory,	Barcelona,	Spain),	
using	 HemosIL	 insertions	 (Werfen	 Instrumentation	 Laboratory),	
FVIII	deficient	plasma,	FXI	deficient	plasma,	FXII	deficient	plasma,	
VWF	antigen,	Thrombin	(Bovine),	and	d-	Dimer	HS	500,	respectively.	
Samples	were	not	diluted	before	the	analysis.	Measurement	of	FVIII,	
FXI,	FXII,	and	fibrinogen	by	the	ACL	TOP	700	involves	a	1:10	dilution	
step.	Measurement	of	VWF:Ag	and	d-	dimer	did	not	involve	a	dilution	
step.	The	corresponding	manufacturer	reference	ranges	were,	FVIII:	
50-	150	IU/dL	(%),	FXI:	65-	150	IU/dL	(%),	FXII:	50-	150	IU/dL	(%),	fi-
brinogen:	2.0-	3.93	g/L,	d-	dimer:	<500	ng/mL	fibrinogen	equivalent	
units	 (FEU),	VWF:Ag:	42.0-	140.8	IU/dL	 (%)	 for	blood	group	O	and	
66.1-	176.3	IU/dL	(%)	for	non-	O	blood	groups.
Laboratory	technicians	were	blinded	to	time	point	and	agent	cor-
responding	to	each	sample.	All	coagulation	factor	levels	were	deter-
mined	within	one	batch.	All	coagulation	factors,	except	for	d-	dimer	
levels	were	measured	in	duplicate.
2.4 | Statistical analysis
Differences	 in	 coagulation	 factor	 levels	before	and	after	 rivaroxa-
ban/apixaban	intake	were	plotted	for	every	participant	and	for	every	
factor	at	the	three	sessions.	We	estimated	the	mean	difference	with	
95%	 confidence	 intervals	 (CIs)	 in	 levels	 of	 the	 coagulation	 factors	
(before	and	after	the	intake	of	rivaroxaban/apixaban)	for	every	par-
ticipant	at	the	three	different	sessions	(within	pair	comparison).	The	
observed	mean	of	 these	paired	differences	 are	presented	both	 as	
absolute	differences	and	as	percentages.	d-	dimer	was	also	assessed	
on	a	natural	 logarithmic	 (Ln)	scale	as	the	distribution	of	d-	dimer	 is	
slightly	skewed.
For	a	post	hoc	sample	size	calculation,	assuming	an	alpha	of	0.05	
and	a	beta	of	0.80,	we	would	need	a	sample	size	of	11	paired	mea-
surements	for	both	rivaroxaban	and	apixaban	separately	to	detect	
a	paired	mean	difference	of	10	IU/dL	or	more	in	FVIII	levels	with	a	
(conservative)	standard	deviation	(SD)	of	10	IU/dL.
3  | RESULTS AND DISCUSSION
The	clinical	characteristics	of	the	participants	and	the	mean	 levels	
of	 the	 coagulation	 factors	 at	 the	 start	 of	 each	 session	 are	 shown	
in	 Table	1.	 In	 both	 the	 rivaroxaban	 and	 apixaban	 trial	 six	 healthy	
male	participants	were	enrolled	and	all	12	completed	the	trial.	The	
mean	age	in	the	rivaroxaban	trial	was	27	(SD	12)	years	and	the	mean	
weight	was	83	(SD	14)	kg,	this	was	26	(SD	7)	years	and	75	(SD	12)	kg	
in	the	apixaban	trial.
Figure	1	 depicts	 the	 difference	 in	 coagulant	 factor	 levels	 be-
tween	 T0	 (before)	 and	 T1	 (after	 rivaroxaban/apixaban	 intake)	 for	
every	participant	at	all	three	sessions.	FVIII:C,	FXI:C,	FXII:C,	d-	dimer	
levels	were	mostly	 lower	after	rivaroxaban/apixaban	intake	and	fi-
brinogen	and	VWF:Ag	levels	changed	only	marginally	if	at	all.
The	 average	 paired	 mean	 differences	 in	 coagulation	 factors	
levels	after	rivaroxaban/apixaban	 intake	are	shown	in	Table	2.	The	
differences	in	levels	after	rivaroxaban	intake	were	−38	IU/dL	(95%	CI	
−43;	−33)	for	FVIII:C,	−29	IU/dL	(95%	CI	−45;	−12)	for	FXI:C,	−22	IU/
dL	 (95%	CI	−43;	−1)	 for	FXII:C,	−0.11	g/L	 (95%	CI	−0.25;	0.03)	 for	
fibrinogen,	 −7	IU/dL	 (95%	CI	 −18;	 3)	 for	VWF:Ag,	 −27	 FEU	ng/mL	
(95%	CI	−50;	−4)	 for	d-	dimer	and	−0.36	 (95%	CI	−0.57;	−0.15)	 for	
Ln	 d-	dimer.	 This	 corresponds	 to	 a	 relative	 difference	 in	 levels	 of	
−33.9%	for	FVIII:C,	−26.9%	for	FXI:C,	and	−18.0%	for	FXII:C.	This	
was	−23.1%	for	d-	dimer,	−7.8%	for	Ln	d-	dimer,	−4.0%	for	fibrinogen,	
and	-8.1%	for	VWF:Ag	levels.
In	the	apixaban	trial	the	paired	mean	differences	were	−29	IU/dL	
(95%	CI	−38;	−21)	for	FVIII:C,	−29	IU/dL	(95%	CI	−36;	−22)	for	FXI:C,	
−19	IU/dL	 (95%	 CI	 −24;	 −15)	 for	 FXII:C,	 −0.18	g/L	 (95%	 CI	 −0.33;	
0.03)	for	fibrinogen,	−52	FEU	ng/mL	(95%	CI	−100;	−4)	for	d-	dimer,	
−0.25	 (−0.60;	0.09)	 for	 Ln	d-	dimer,	 and	1	IU/dL	 (95%	CI	−7;	9)	 for	
VWF:Ag.	This	 corresponded	 to	a	 relative	difference	of	 -26.3%	 for	
TABLE  1 Clinical	characteristics	and	levels	of	the	coagulation	
factors	at	start	of	each	session
Rivaroxaban Apixaban
Participants,	n 6 6
Age,	mean	(SD) 27	(12) 26	(7)
Weight	in	kg,	mean	(SD) 83	(14) 75	(12)
Mean	levels	(SD)	at	T0,	start	of	each	session	before	rivaroxaban/
apixaban	intake
FVIII:C	(IU/dL)
Session	1 113	(25) 122	(16)
Session	2a 115	(22) 105	(14)
Session	3a 107	(16) 114	(14)
FXI:C	(IU/dL)
Session	1 109	(20) 122	(9)
Session	2a 110	(14) 117	(13)
Session	3a 106	(12) 121	(13)
FXII:C	(IU/dL)
Session	1 120	(24) 104	(36)
Session	2a 122	(18) 103	(36)
Session	3a 123	(14) 105	(36)
Fibrinogen	(g/L)
Session	1 2.87	(0.98) 3.08	(0.67)
Session	2a 2.79	(1.00) 2.25	(0.38)
Session	3a 2.59	(0.86) 2.35	(0.34)
VWF:Ag	(IU/dL)
Session	1 99	(28) 123	(23)
Session	2a 105	(36) 100	(15)
Session	3a 92	(25) 104	(16)
d-	dimer	(FEU	ng/mL)
Session	1 116	(60) 208	(141)
Session	2a 110	(57) 147	(104)
Session	3a 126	(48) 136	(82)
FEU,	fibrinogen	equivalent	units;	SD,	standard	deviation.
aAfter	a	washout	period	of	at	least	15	days	after	previous	session.
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FVIII:C,	−24.2%	for	FXI:C,	and	-19.2%	for	FXII:C.	This	was	−31.7%	
for	d-	dimer,	-5.4%	for	Ln	d-	dimer,	−7.0%	for	fibrinogen,	and	+0.9%	
for	VWF:Ag	levels.
Finally,	 we	 assessed	 whether	 there	 was	 a	 linear	 relation-
ship	 between	 measured	 FVIII:C	 and	 d-	dimer	 levels	 before	 and	
after	 rivaroxaban/apixaban	 intake.	 As	 depicted	 in	 Figure	2A,	
we	 observed	 a	 linear	 association	 between	 FVIII:C	 levels	 before	
rivaroxaban/apixaban	 intake	and	 the	decrease	 in	 levels	 after	 in-
take.	For	d-	dimer	levels	there	also	appeared	to	be	a	linear	associ-
ation,	although	levels	were	low	overall	(Figure	2B).	This	is	relevant	
as	a	 linear	association	would	make	 these	measurements	still	us-
able	as	a	predictor,	whereas	no	association	(eg,	random	influence	
of	the	anticoagulant	intake	on	the	measurement)	could	render	the	
predictor	unusable.
F IGURE  1 Difference	in	coagulation	factor	levels	before	(T0)	and	after	(T1)	rivaroxaban/apixaban	intake	for	every	participant	at	all	
three	sessions.	Black	bars	indicate	the	difference	in	the	factor	at	the	first	session,	the	grey	and	white	bar	the	second	and	third	session,	
respectively.	Bars	pointing	down	indicate	a	lower	factor	level	after	rivaroxaban/apixaban	intake,	bars	pointing	up	indicate	higher	levels.	The	
order	of	participants	is	the	same	in	all	figures.	Please	note	that	the	y-	axis	(and	unit)	is	different	for	d-	dimer	(in	fibrinogen	equivalent	units)	
and	fibrinogen.*124	IU/dL.	†Measurement	missing
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As	 also	 reported	 by	 Tichelaar	 and	 colleagues,11	 FVIII:C	 mea-
surements	seem	to	be	affected	by	rivaroxaban	intake.	We	observed	
the	same	effect	for	FXI:C	and	FXII:C	measurements	for	both	rivar-
oxaban	 and	 apixaban	 intake.	 As	 was	 also	 reported	 by	Mani	 et	al,	
VWF:Ag	measurements	did	not	seem	to	be	affected	by	a	low	dose	
of	rivaroxaban	 (10	mg	daily)	 intake,	although	 in	their	study	the	av-
erage	VWF:Ag	study	levels	were	high,	likely	due	to	the	postsurgical	
status	of	the	participants	and	no	measurement	was	done	before	ri-
varoxaban	intake.12	In	addition,	both	VWF:Ag	as	well	as	VWF	activ-
ity	measurements	were	not	affected	in	an	in	vitro	study	with	drug	
enriched	samples	of	rivaroxaban	and	apixaban.19 In other studies in 
which	factor	Xa	inhibitors	were	added	to	human	plasma	ex	vivo,	fi-
brinogen	measurements	were	reported	not	to	be	affected.17-19 Our 
study	confirm	 these	 findings	 in	healthy	men	on	 therapeutic	doses	
of	 rivaroxaban/apixaban	and	by	 comparing	 coagulation	 factor	 lev-
els	before	and	after	intake.	Intake	of	rivaroxaban	or	apixaban	could	
influence	these	coagulation	factor	measurements	either	due	to	a	di-
rect	effect	on	the	coagulant	factors	(eg,	the	actual	in	vivo	levels	are	
lower	due	to	the	effects	of	 the	agent)	or	due	to	 interference	with	
the	assay	(eg,	the	actual	in	vivo	levels	are	unchanged,	only	the	mea-
surement	is	influenced).	In	previous	studies	sample	plasma	dilutions	
partially	 resolved	 the	 difference	 in	 measured	 levels	 after	 spiking	
with	DOAC,	indicating	that	interference	with	the	assay	is	the	most	
feasible	explanation.11,12
A	strength	of	this	study	is	its	controlled	design,	where	at	three	
sessions	 (with	 a	washout	period	 in	between)	blood	was	 taken	 im-
mediately	before	rivaroxaban/apixaban	intake	and	three	hours	after	
intake.	Where	most	previous	studies	were	 limited	 to	ex	vivo	or	 in	
TABLE  2 Effects	of	rivaroxaban	and	apixaban	on	coagulation	factor	measurements
Mean (SD) FVIII:C FXI:C FXII:C Fibrinogen VWF:Ag d- dimer Ln d- dimer
Rivaroxaban
T	=	0 112	(20) 108	(15) 122	(18) 2.75	(0.92) 99	(28) 117	(54) 4.59	(0.78)
T	=	1 74	(19) 79	(11) 100	(23) 2.64	(0.93) 91	(27) 90	(36) 4.23	(0.94)
Mean 
differencea
−38	(−43	to	−33) −29	(−45	to	−12) −22	(−43	to	−1) −0.11	(−0.25	
to	0.03)
−7	(−18	to	3) −27	(−50	to	−4) −0.36	(−0.57	to	
−0.15)
Apixaban
T	=	0 114	(12) 120	(11) 104	(36) 2.56	(0.36) 109	(16) 164	(103) 4.84	(0.78)
T	=	1 84	(6) 91	(14) 84	(33) 2.38	(0.25) 110	(12) 112	(65) 4.58	(0.54)
Mean 
differencea
−29	(−38	to	−21) −29	(−36	to	−22) −19	(−24	to	−15) −0.18	(−0.33	
to	0.03)
1	(−7	to	9) −52	(−100	to	−4) −0.25	(−0.60	to	
0.09)
Fibrinogen	in	g/L,	d-	dimer	in	fibrinogen	equivalent	units	ng/mL,	other	variables	n	IU/dL.	SD,	standard	deviation;	VWF,	von	Willebrand	factor.
aWithin	pair	comparison	with	(95%	confidence	interval).
F IGURE  2 Association	between	(A)	
FVIII:C	and	(B)	d-	dimer	levels	in	fibrinogen	
equivalent	units	(FEU)	ng/mL	before	and	
after	intake	of	rivaroxaban/apixaban.	
Results	are	shown	for	rivaroxaban	and	
apixaban
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vitro	settings,	we	investigated	the	effects	of	rivaroxaban/apixaban	
in	human	volunteers	on	 therapeutic	doses	of	 the	agents.	A	 limita-
tion	of	this	study	is	that	it	was	performed	in	healthy	individuals	with	
generally	low	d-	dimer	levels	(often	below	the	official	detection	limit	
of	203	ng/mL	FEU),	and	this	finding	might	therefore	not	be	directly	
extrapolated	to	the	anticoagulant	using	patient	population.	In	an	in	
vitro study d-	dimer	measurements	were	not	 influenced	by	enrich-
ing	 samples	with	 rivaroxaban	or	 apixaban.19	 In	 addition,	 all	 partic-
ipants	were	men	hereby	 limiting	 the	generalizability	of	 the	 results	
to women.
The	 results	 of	 our	 study	 are	 relevant	 to	 clinical	 practice:	
d-	dimer,	 FVIII:C,	 FXI:C,	 and	 FXII:C	 measurements	 in	 patients	
using	 rivaroxaban	or	apixaban	should	be	 interpreted	with	cau-
tion	 as	 they	 are	 probably	 different	 from	 as	 when	 measured	
without	 rivaroxaban/apixaban	use.	As	 there	was	a	 linear	asso-
ciation	 in	 the	decrease	of	FVIII:C	measurement	after	 intake	of	
rivaroxaban/apixaban,	 FVIII:C	might	 still	 be	 a	 useful	 predictor	
while	using	rivaroxaban	or	apixaban,	however,	this	requires	fur-
ther	validation.	VWF:Ag	was	hardly,	 if	at	all,	 influenced	by	the	
treatment	 and	 was	 previously	 found	 to	 have	 a	 similar	 predic-
tive	 performance	 to	 FVIII:C	 in	 the	MEGA	 follow-	up	 study.5 In 
this	 study,	 the	 risk	 of	 a	 venous	 thromboembolism	 recurrence	
increased	stepwise	with	the	highest	risk	observed	for	FVIII	lev-
els	>225	IU/dL:	hazard	ratio	(HR)	4.6	(95%	CI	2.9-	7.5),	100	IU/dL	
as	reference.	This	pattern	was	similar	for	VWF:Ag	levels,	where	
the	observed	risk	was	also	highest	at	levels	>225	IU/dL:	HR	4.1	
(95%	CI	2.6-	6.5),	<100	IU/dL	as	reference.5	Thus,	VWF:Ag	might	
have	a	role	in	future	prediction	models	for	venous	thromboem-
bolism	 recurrence	 for	 both	 patients	 off	 anticoagulant	 therapy	
and	patients	using	a	factor	Xa	inhibitor	(at	least	for	rivaroxaban	
and	apixaban).
In	conclusion,	FVIII:C,	FXI:C,	FXII:C,	and	d-	dimer	measurements	
were	 influenced	and	decreased	by	rivaroxaban	or	apixaban	 intake.	
Fibrinogen	and	VWF:Ag	measurements	were	not	affected	by	rivar-
oxaban/apixaban	intake.
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